Position in JNJ
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$3,504,278
+$210,449 QoQ
Shares Held
13,798
+2.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
1.66%
of 13F equity value
Holder Rank
#1,880
of 4,664 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 2%
Shared 0%
None 98%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Purkiss Capital Advisors LLC holds $8,883,228 across 7 Drug Manufacturers - General names. JNJ ranks #1 (39.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
This page
|
13,798 | $3,504,278 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
36,627 | $2,110,447 | |
| 3 | LLY |
ELI LILLY & Co
|
939 | $1,126,264 | |
| 4 | ABBV |
AbbVie Inc.
|
4,355 | $1,095,892 | |
| 5 | MRK |
Merck & Co., Inc.
|
3,751 | $482,003 | |
| 6 | AMGN |
Amgen Inc
|
898 | $325,183 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
1,893 | $239,161 |
All Filings in JNJ
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,504,278 | 13,798 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $3,293,829 | 13,475 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $2,797,550 | 13,518 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $2,542,293 | 13,711 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $2,182,644 | 14,289 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $2,268,525 | 13,679 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $1,838,843 | 12,715 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||